Study on the Effectiveness of the MTT24.5 Cognitive Training Program on Cognitive Skills, Brain Volume, and Activation
MTT245Cog
Analysis of Efficacy of the Mental Training Tech 245: a Novel Method of Cognitive Stimulation Based on Brain Neuroplastic Ability
1 other identifier
interventional
75
1 country
1
Brief Summary
The goal of this study is to evaluate the effectiveness of a cognitive training program called Mental Training Tech 24.5 (MTT24.5). The program aims to enhance brain function and neuronal plasticity in adults who do not have any clinical cognitive impairment. This study will help determine if MTT24.5 improves cognitive abilities and affects brain volume and activation. The Main Questions it aims to answer are: Does MTT24.5 improve overall cognitive performance and specific areas like memory, attention, and language skills? What effects does MTT24.5 have on brain volume and activation? How well do participants follow the program, and what are their response patterns? Study Design
- Researchers will compare the results of participation in the MTT24.5 training versus a control group with no intervention. Participants will be randomly assigned to either the MTT24.5 program or the control group.
- The study involves adults aged 30 and older from the general population who do not have clinical cognitive impairment.
- The intervention includes attending 12 weekly in-person sessions, each lasting about 2 hours, for a total of 24.5 hours.
- The study will assess cognitive performance, brain volume, and activation, as well as monitor adherence to the program and response patterns. Participants will:
- Engage in the MTT24.5 program or the control condition as assigned.
- Complete cognitive assessments to measure performance in various domains.
- Undergo brain imaging to evaluate changes in brain volume and activation.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for not_applicable
Started Mar 2023
Shorter than P25 for not_applicable
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
March 2, 2023
CompletedPrimary Completion
Last participant's last visit for primary outcome
August 1, 2023
CompletedStudy Completion
Last participant's last visit for all outcomes
October 30, 2023
CompletedFirst Submitted
Initial submission to the registry
August 3, 2024
CompletedFirst Posted
Study publicly available on registry
August 12, 2024
CompletedAugust 14, 2024
August 1, 2024
5 months
August 3, 2024
August 11, 2024
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Change in Global Cognitive Ability
The primary study outcome, cognitive ability changes, was assessed through the difference between the post intervention Addenbrooke's Cognitive Examination III (ACE) score and the pre intervention ACE score. This score ranges from 0 to 100. he ACE Score ranges from 0 to 100. A value less than 85 es considered as cognitive moderate impairment.
immediately after the intervention
Secondary Outcomes (3)
Change in memory, and /or attention, and/or verbal fluency, and/or language, and/or visuospatial skills abilities.
immediately after the intervention
Rate of Adherence
immediately after the intervention
Change in Brain Volume and Activation
immediately after the intervention
Study Arms (2)
Intervention group-MTT24.5
ACTIVE COMPARATORSubjects are assigned to 12 cognitive training in-person sessions of the MTT245 program by a validated trainer. Cognitive evaluations are made initially week 1 and at the end of the intervention at week 12.
Control group
NO INTERVENTIONSubjects are assigned to a controlled arm whereas no intervention were done. They should underwent the same cognitive evaluations than active comparator at week 1 and 12.
Interventions
MTT24.5 consists in the learning of 40 new datas or knowledges, along 24.5 hours distributted on classes or sessions, during which an average of 3.5 new pieces of knowledge are taught and reinforced through training. Participants are trained using 4 techniques assigned to each new piece of information from a total of 100 available techniques. These techniques include the use of non-dominant skills, literacy in Braille for sighted individuals, and performing 5 actions simultaneously. Each technique is designed to aid in the memorization and learning of new knowledge
Eligibility Criteria
You may qualify if:
- Adults aged 21 years and above.
- Ability to understand instructions for the training tasks.
- Addenbrooke Cognitive Examination score \>70.
You may not qualify if:
- Planned absences that would hinder participation in the program.
- Hearing, visual, or motor deficits that would impede participation in the program.
- History of severe degenerative neurological diseases, as these conditions may significantly impact brain plasticity and cognitive abilities.
- History of severe psychiatric disorders, as they may influence brain reorganization and complicate the interpretation of results.
- Unstable treatment or planned changes in medication that may affect brain function and alter results.
- History of current or recent excessive substance use (within the past 6 months), including alcohol or drugs, as these substances may influence brain function and neuroplasticity.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Espacio Santa Maria
San Isidro, Buenos Aires, 1643, Argentina
Related Publications (8)
Livingston G, Huntley J, Sommerlad A, Ames D, Ballard C, Banerjee S, Brayne C, Burns A, Cohen-Mansfield J, Cooper C, Costafreda SG, Dias A, Fox N, Gitlin LN, Howard R, Kales HC, Kivimaki M, Larson EB, Ogunniyi A, Orgeta V, Ritchie K, Rockwood K, Sampson EL, Samus Q, Schneider LS, Selbaek G, Teri L, Mukadam N. Dementia prevention, intervention, and care: 2020 report of the Lancet Commission. Lancet. 2020 Aug 8;396(10248):413-446. doi: 10.1016/S0140-6736(20)30367-6. Epub 2020 Jul 30. No abstract available.
PMID: 32738937BACKGROUNDLindenberger U. Human cognitive aging: corriger la fortune? Science. 2014 Oct 31;346(6209):572-8. doi: 10.1126/science.1254403.
PMID: 25359964BACKGROUNDBall K, Berch DB, Helmers KF, Jobe JB, Leveck MD, Marsiske M, Morris JN, Rebok GW, Smith DM, Tennstedt SL, Unverzagt FW, Willis SL; Advanced Cognitive Training for Independent and Vital Elderly Study Group. Effects of cognitive training interventions with older adults: a randomized controlled trial. JAMA. 2002 Nov 13;288(18):2271-81. doi: 10.1001/jama.288.18.2271.
PMID: 12425704BACKGROUNDSnowdon DA; Nun Study. Healthy aging and dementia: findings from the Nun Study. Ann Intern Med. 2003 Sep 2;139(5 Pt 2):450-4. doi: 10.7326/0003-4819-139-5_part_2-200309021-00014.
PMID: 12965975BACKGROUNDRebok GW, Ball K, Guey LT, Jones RN, Kim HY, King JW, Marsiske M, Morris JN, Tennstedt SL, Unverzagt FW, Willis SL; ACTIVE Study Group. Ten-year effects of the advanced cognitive training for independent and vital elderly cognitive training trial on cognition and everyday functioning in older adults. J Am Geriatr Soc. 2014 Jan;62(1):16-24. doi: 10.1111/jgs.12607. Epub 2014 Jan 13.
PMID: 24417410BACKGROUNDFeingold A. New Approaches for Estimation of Effect Sizes and their Confidence Intervals for Treatment Effects from Randomized Controlled Trials. Quant Method Psychol. 2019;15(2):96-111. doi: 10.20982/tqmp.15.2.p096.
PMID: 32775313BACKGROUNDMasic V, Secic A, Trost Bobic T, Femec L. Neuroplasticity and Braille reading. Acta Clin Croat. 2020 Mar;59(1):147-153. doi: 10.20471/acc.2020.59.01.18.
PMID: 32724286BACKGROUNDKotliar C, Olmos L, Koretzky M, Jauregui R, Delia T, Cingolani O. A new program for systematically enhancing cognitive reserve in healthy adults: A pilot randomized active-controlled clinical trial. PLoS One. 2025 Oct 1;20(10):e0331193. doi: 10.1371/journal.pone.0331193. eCollection 2025.
PMID: 41032503DERIVED
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Carol V Kotliar, PhD
BIO
- PRINCIPAL INVESTIGATOR
Carol V Kotliar, PhD
Institute for Biomedical Research, CONICET
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- NONE
- Purpose
- PREVENTION
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Chief Clinical Research Laboratory
Study Record Dates
First Submitted
August 3, 2024
First Posted
August 12, 2024
Study Start
March 2, 2023
Primary Completion
August 1, 2023
Study Completion
October 30, 2023
Last Updated
August 14, 2024
Record last verified: 2024-08
Data Sharing
- IPD Sharing
- Will share
- Shared Documents
- STUDY PROTOCOL, SAP, ANALYTIC CODE
- Time Frame
- At the time of publication in a peer review journal
- Access Criteria
- By written request to the PI, accompanied by a letter explaining objectives of the IPD to be shared and research group institution or antecedents of the individual if not an institution.
At the time of publication, and upon aproval of the request by a scientific board, all IPD that underlie results in a publication will be shared.